New molecules in the therapy of chronic graft-versus-host disease

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Chronic graft-versus-host disease (cGvHD) is a significant complication after allogeneic hematopoietic cell transplantation.
• Multiple lines of immunosuppressive therapy are often required for cGvHD management.

Purpose of the Study:

• To review the clinical positioning, strengths, and safety of newly approved and emerging targeted therapies for cGvHD.
• To provide an updated understanding of treatment strategies in the context of evolving therapeutic options.

Main Methods:

• Review of recently approved and investigational agents for cGvHD.
• Analysis of clinical trial data and published literature on targeted therapies.
• Evaluation of drug efficacy, safety profiles, and organ-specific responses.

Main Results:

• Approved agents like ibrutinib, ruxolitinib, belumosudil, and axatilimab target cGvHD after specific treatment failures.
• Novel compounds targeting inflammatory and fibrotic pathways show promise but have variable safety and efficacy.
• Prior Janus kinase inhibitor exposure impacts treatment sequencing; outcome discrepancies exist.

Conclusions:

• Therapeutic decisions for cGvHD should consider organ involvement, prior treatments, and tolerability.
• Emerging therapies enable precise modulation of inflammation and fibrosis.
• Personalized and combinatorial approaches are advancing for advanced-stage cGvHD.